Report Detail

Pharma & Healthcare Cipla Ltd (CIPLA) - Financial and Strategic SWOT Analysis Review

  • RnM2387967
  • |
  • 08 July, 2019
  • |
  • Global
  • |
  • 53 Pages
  • |
  • GlobalData
  • |
  • Pharma & Healthcare

Cipla Ltd (CIPLA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Cipla Ltd (Cipla) is a pharmaceutical company, which manufactures and distributes branded medicines, generics and active pharmaceutical ingredients (APIs). It offers products for the treatment of various conditions such as cardiovascular and pediatric diseases, dermatological and cosmetological conditions, HIV/AIDS, diabetes, hepatitis, infectious diseases and critical care, malaria, cancer, neurological, ophthalmic, respiratory and urological conditions, osteoporosis and women's health. The company also operates in consumer healthcare and biosimilar businesses. Cipla manufactures metered-dose inhaler devices, spacers and related devices; and conducts R&D to develop new medicines and drug delivery systems. The company has operations in India, US, Canada, South Africa and major regulated and emerging markets among others. Cipla is headquartered in Mumbai, Maharashtra, India.

Cipla Ltd Key Recent Developments

Jun 21,2019: Cipla: Resignation of Mr. Peter Lankau as Independent Director of the Company
Jun 10,2019: Cipla: Closure Of USFDA inspection at Kurkumbh Manufacturing Facility
May 22,2019: Cipla reports Q4 and FY19 results
May 17,2019: USFDA post-approval inspection completed at Cipla's Indore manufacturing facility
Apr 22,2019: Cipla names Dr. Raju Mistry as Global Chief People Officer

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company


Table of Contents

    Table of Contents

      List of Tables

        List of Figures

          Section 1 - About the Company

            Cipla Ltd - Key Facts

              Cipla Ltd - Key Employees

                Cipla Ltd - Key Employee Biographies

                  Cipla Ltd - Major Products and Services

                    Cipla Ltd - History

                      Cipla Ltd - Locations And Subsidiaries

                        Head Office

                          Other Locations & Subsidiaries

                            Section 2 – Company Analysis

                              Company Overview

                                Cipla Ltd - Business Description

                                  Business Segment: New Ventures

                                    Overview

                                      Performance

                                        Business Segment: Pharmaceuticals

                                          Overview

                                            Performance

                                              R&D Overview

                                                Cipla Ltd - Corporate Strategy

                                                  Cipla Ltd - SWOT Analysis

                                                    SWOT Analysis - Overview

                                                      Cipla Ltd - Strengths

                                                        Cipla Ltd - Weaknesses

                                                          Cipla Ltd - Opportunities

                                                            Cipla Ltd - Threats

                                                              Cipla Ltd - Key Competitors

                                                                Section 3 – Company Financial Ratios

                                                                  Financial Ratios - Capital Market Ratios

                                                                    Financial Ratios - Annual Ratios

                                                                      Performance Chart

                                                                        Financial Performance

                                                                          Financial Ratios - Interim Ratios

                                                                            Financial Ratios - Ratio Charts

                                                                              Section 4 – Company’s Lifesciences, Power Financial Deals and Alliances

                                                                                Cipla Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

                                                                                  Cipla Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019

                                                                                    Cipla Ltd, Recent Deals Summary

                                                                                      Section 5 – Company’s Recent Developments

                                                                                        Jun 21, 2019: Cipla: Resignation of Mr. Peter Lankau as Independent Director of the Company

                                                                                          Jun 10, 2019: Cipla: Closure Of USFDA inspection at Kurkumbh Manufacturing Facility

                                                                                            May 22, 2019: Cipla reports Q4 and FY19 results

                                                                                              May 17, 2019: USFDA post-approval inspection completed at Cipla's Indore manufacturing facility

                                                                                                Apr 22, 2019: Cipla names Dr. Raju Mistry as Global Chief People Officer

                                                                                                  Apr 17, 2019: Pulmatrix and Cipla collaborate to develop asthma drug

                                                                                                    Mar 31, 2019: Cipla: Product specific pre-approval (PAI) and Good Manufacturing Practices (GMP) inspection at its Kurkumbh plant

                                                                                                      Feb 18, 2019: Cipla and Wellthy Therapeutics announce partnership to offer digital therapeutics for diabetes and cardiovascular diseases

                                                                                                        Oct 04, 2018: Cipla:Inspection by the United States Food and Drug Administration (USFDA) at the Goa manufacturing facility

                                                                                                          Sep 10, 2018: Understanding depression and related symptoms key to suicide prevention in SA

                                                                                                            Section 6 – Appendix

                                                                                                              Methodology

                                                                                                                Ratio Definitions

                                                                                                                  About GlobalData

                                                                                                                    Contact Us

                                                                                                                      Disclaimer

                                                                                                                      Summary:
                                                                                                                      Get latest Market Research Reports on Cipla Ltd (CIPLA). Industry analysis & Market Report on Cipla Ltd (CIPLA) is a syndicated market report, published as Cipla Ltd (CIPLA) - Financial and Strategic SWOT Analysis Review. It is complete Research Study and Industry Analysis of Cipla Ltd (CIPLA) market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

                                                                                                                      Last updated on

                                                                                                                      REPORT YOU MIGHT BE INTERESTED

                                                                                                                      Purchase this Report

                                                                                                                      $500.00
                                                                                                                      $1,000.00
                                                                                                                      $1,500.00
                                                                                                                      398.50
                                                                                                                      797.00
                                                                                                                      1,195.50
                                                                                                                      465.00
                                                                                                                      930.00
                                                                                                                      1,395.00
                                                                                                                      76,440.00
                                                                                                                      152,880.00
                                                                                                                      229,320.00
                                                                                                                      41,715.00
                                                                                                                      83,430.00
                                                                                                                      125,145.00
                                                                                                                      Credit card Logo

                                                                                                                      Related Reports


                                                                                                                      Reason to Buy

                                                                                                                      Request for Sample of this report